Risk Factors for Complications in Children with Staphylococcus aureus Bacteremia - 24/04/19
, Daniele Dona, MD 2, Marni B. Jacobs, MPH, PhD 3, Jeffrey S. Gerber, MD, PhD 2Abstract |
Objectives |
To determine risk factors for complications in children with Staphylococcus aureus (S aureus) bacteremia, including methicillin resistance.
Study design |
Single center, retrospective cohort study of children ≤18 years of age hospitalized with S aureus bacteremia. We compared clinical characteristics and outcomes between those with methicillin-sensitive S aureus (MSSA) and methicillin-resistant S aureus (MRSA) bacteremia. Multivariate regression models identified risk factors associated with developing complications and with longer duration of bacteremia.
Results |
We identified 394 episodes of S aureus bacteremia, 279 (70.8%) with MSSA, and 115 (29.2%) with MRSA. Primary site of infection was catheter-related in 34%, musculoskeletal in 30%, skin/soft tissue in 10.2%, pneumonia in 6.4%, and endovascular in 6.6%. Eight children (2.0%) died within 30 days because of S aureus bacteremia, 15 (3.5%) had recurrence within 30 days, and 38 (9.6%) had complications including septic emboli or a metastatic focus of infection. Methicillin resistance was associated with development of a complication (aOR 3.31; 95% CI 1.60-6.85), and catheter-related infections were less likely to be associated with a complication (aOR 0.40; 95% CI 0.15-1.03). In a Poisson regression analysis on duration of bacteremia, methicillin resistance, musculoskeletal infection, endovascular infection, black race, and delayed intervention for source control were significantly associated with longer duration of bacteremia.
Conclusions |
In this cohort of children with S aureus bacteremia, MRSA infections ere associated with longer duration of bacteremia and a higher likelihood of complications.
Le texte complet de cet article est disponible en PDF.Keywords : Staphylococcus aureus, bacteremia, MRSA, children
Abbreviations : CHOP, MIC, MRSA, MSSA, S aureus
Plan
| Supported by a National Institutes of Health Training grant award to the Center for Pharmacoepidemiology Research and Training grant of the University of Pennsylvania (T32 GM-075766). The authors declare no conflicts of interest. |
Vol 208
P. 214 - mai 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
